Filing Details
- Accession Number:
- 0001553350-22-000209
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2022-03-09 16:00:14
- Reporting Period:
- 2021-09-13
- Accepted Time:
- 2022-03-09 16:00:14
- Original Submission Date:
- 2021-09-14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
788920 | Pro Dex Inc | PDEX | Surgical & Medical Instruments & Apparatus (3841) | 841261240 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1797788 | Kramer Marie Katrina Philp | 2361 Mcgaw Avenue Irvine CA 92614 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-09-13 | 4,000 | $24.41 | 10,796 | No | 4 | P | Indirect | By Spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By Spouse |
Footnotes
- On September 14, 2021, the reporting person filed a Form 4 that inadvertently reported that her spouse acquired 3,468 shares of the issuer's common stock on September 13, 2021 at a weighted average exercise price of $24.41 per share and that, following that acquisition, she beneficially owned 10,264 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person's spouse acquired 4,000 shares of the issuer's common stock on that same date and at that same weighted average exercise price, resulting in the reporting person beneficially owning 10,796 shares of the issuer's common stock.
- The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $24.04 to $25.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.